The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

GOP leaders are racing to try to get the bill to the White House by July 4. The multi-trillion-dollar bill would unlock tax ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...